J&J's Risperdal Consta approved for bipolar disorder in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Johnson & Johnson's bi-weekly atypical antipsychotic, Risperdal Consta (risperidone) long-acting injection, as both monotherapy and adjunctive therapy to lithium and valproate, in the maintenance treatment of bipolar I disorder.